ライフサイエンスコーパス: UC

1 UC has evolved into a global burden given its high incid

2 UC risk was also increased among men whose youngest chil

3 ted adverse events occurred in 5.3% vs 7.0% (UC) and 8.7% vs 19.0% (CD) of VDZ vs anti-TNFalpha patie

4 om 5 intervention clusters and 1,097 from 10 UC clusters were recruited between November 2015 and Apr

5 A total of 133 UC (76 VDZ; 57 anti-TNFalpha) and 174 CD (69 VDZ; 105 an

6 s, each reflecting key aspects from the 2018 UC Davis symposium: MEC (how mechanical load influences

7 atients with UC treated in the UNIFI phase 3 UC clinical studies of ustekinumab.

8 s of follow-up, 1,523 developed CD and 3,323 UC.

9 4 SB and 2 colonic cohorts; n = 495; n = 387 UC; n = 94 non-IBD), we analyzed the relationship betwee

10 onstrated restricted formation of U(3)Si(5), UC, and U(20)Si(16)C(3)/USi phases at the interface.

11 nd 157 primary and metastatic tumors from 80 UC patients.

12 The data included 4,304 CD cases and 8,866 UC cases.

13 ts with microscopic colitis compared with 94 UC and 42 CD cases in population comparators.

14 A UC-100 score of 25 or less corresponds to a 95% probabil

15 Random forest modeling differentiated active UC from active CD in colonic mucosa and blood samples; t

16 mples from patients receiving FMT for active UC and stool samples from donors, we associated specific

17 genes and function across cohorts in active UC, and that increasing disease severity is notable for

18 of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-bl

19 with active CD differed from those of active UC in that the peripheral blood mononuclear cells from p

20 ouble-blind trial of 81 patients with active UC randomly assigned to groups that received an initial

21 cisplatin-ineligible patients with advanced UC and is associated with prolonged OS, particularly wit

22 uently are present in patients with advanced UC.

23 ks of CD (OR = 1.22, 95% CI: 1.01, 1.49) and UC (OR = 1.15, 95% CI: 1.02, 1.30) than childless men.

24 facial phases U(20)Si(16)C(3), U(3)Si(5) and UC reveal a thermodynamic driving force for generating d

25 from patients with active or inactive CD and UC and controls.

26 non-inflamed colonic segments in both CD and UC differ in microbiota composition and epigenetic profi

27 ciated with an increased incidence of CD and UC up to 40 years later.

28 The 10-year absolute excess risks of CD and UC were 0.9 (95% CI 0.7-1.1) and 2.6 (95% CI 2.2-2.9) pe

29 heir unaffected siblings, the aHRs of CD and UC were 5.4 (95% CI 3.2-9.2) and 9.4 (95% CI 6.4-13.8),

30 Self-reported CD and UC were confirmed by medical record review.

31 and colonic ACE2 expression in active CD and UC were restored by anti-cytokine therapy, most notably

32 nor acknowledged differences between CD and UC.

33 was associated with increased risk of CD and UC.

34 mic treatment had the longest time to CD and UC.

35 d a 4 symptom components solution for CD and UC.

36 tic risk between CC, celiac disease, CD, and UC, which supports clinical observations of comorbidity.

37 these alternative pre-F VLPs, the UC-2 F and UC-3 F VLPs, stimulated in mice higher titers of neutral

38 lonic CD8(+) T-cell phenotypes in health and UC, define their clonal relationships and characterize t

39 %/CD 36.9%), passage of blood from the anus (UC 59.7%/CD 32.1%), and anxiety about distance from bath

40 ), and anxiety about distance from bathroom (UC 59%/CD 38.7%).

41 cal proteolytic and elastase activity before UC onset.

42 5 symptoms with greatest differences between UC and CD were passage of blood with BM (UC 86.6%/CD 45.

43 lood with BM (UC 86.6%/CD 45.3%), urgent BM (UC 82.5%/CD 63.9%), passage of mucus with BM (UC 67.7%/C

44 C 82.5%/CD 63.9%), passage of mucus with BM (UC 67.7%/CD 36.9%), passage of blood from the anus (UC 5

45 een UC and CD were passage of blood with BM (UC 86.6%/CD 45.3%), urgent BM (UC 82.5%/CD 63.9%), passa

46 ndria derived using FMMS to those derived by UC.

47 ious germline variants in urothelial cancer (UC) are not fully characterized.

48 Urothelial cancers (UCs) have a substantial hereditary component, but, other

49 pentasilicide (U(3)Si(5)), uranium carbide (UC), U(20)Si(16)C(3), and uranium silicide (USi) phases

50 as become the goal for urothelial carcinoma (UC) diagnosis and surveillance.

51 al oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients.

52 Urothelial carcinoma (UC) is a common disease causing significant morbidity an

53 c cisplatin-ineligible urothelial carcinoma (UC).

54 utilized a series of urothelial carcinomas (UCs) by tissue microarray, on which histologic variants

55 In the United States, urgent care (UC) encounters are increasing and have high rates of ina

56 omly assigned to intervention or usual care (UC) in a 1:2 ratio.

57 trial showed that compared with usual care (UC), offering same-day (SD) antiretroviral therapy (ART)

58 ipants were randomly assigned to usual care (UC; n = 24) or intervention (n = 23) between 8 and 14 we

59 ing genotype data on control samples and CD, UC, and celiac disease cases were provided by the respec

60 vitamin D (CD), and H pylori infection (CD, UC, and IBD).

61 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients.

62 queried for patients with a diagnosis of CD, UC, malignancy, or benign disease (diverticular disease,

63 Our aim is to characterize UC in elderly-onset patients followed at our Inflammator

64 n monitor AzoR activity in acute and chronic UC mice models.

65 of Crohn disease (CD) or ulcerative colitis (UC) among men and women aged 18-81 years in 2011-2016.

66 ed 323 incident cases of ulcerative colitis (UC) and 108 incident cases of Crohn's disease (CD) in pa

67 mpaired in patients with ulcerative colitis (UC) and renders UC-HMA mice more susceptible to CDI.

68 of prognostic factors in ulcerative colitis (UC) could improve patient management and reduce complica

69 Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinica

70 Crohn's disease (CD) and ulcerative colitis (UC) have been considered as disorders that affect indivi

71 f Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and c

72 ts effectiveness against ulcerative colitis (UC) in a mouse model.

73 Incidence of ulcerative colitis (UC) in elderly population is increasing because of agein

74 Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown a

75 Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC).

76 Ulcerative colitis (UC) is one of the main types of chronic inflammatory dis

77 ease activity scoring in ulcerative colitis (UC) is useful in clinical practice but done infrequently

78 c treatment outcomes for ulcerative colitis (UC) or Crohn's disease (CD) patients are limited.

79 ed the GMSI in 77 CD and ulcerative colitis (UC) patients (24 low and 53 normal GMSI).

80 ohn's disease (CD) and 6 ulcerative colitis (UC) patients and compared them to samples from 16 contro

81 Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively.

82 subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to severe dis

83 +) T cells in health and ulcerative colitis (UC) using single-cell transcriptomics with T-cell recept

84 my-treated patients with ulcerative colitis (UC) versus controls (familial adenomatous polyposis [FAP

85 sponses of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

86 As is known, ulcerative colitis (UC), a chronic inflammatory disease, is closely related

87 nd Crohn's disease (CD), ulcerative colitis (UC), and celiac disease.

88 in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls.

89 Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastro

90 owel diseases, including ulcerative colitis (UC), but the causality and mechanisms remain unknown.

91 levated in patients with ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC).

92 patients suffering from ulcerative colitis (UC), in which first-time treatment with vedolizumab was

93 Crohn's disease (CD) and ulcerative colitis (UC), is a disease associated with dysbiosis, resulting i

94 The economic burden of ulcerative colitis (UC), specifically related to indirect costs, is not exte

95 robiota of patients with ulcerative colitis (UC).

96 Crohn's disease (CD) and ulcerative colitis (UC).

97 ately to severely active ulcerative colitis (UC).

98 ovement in patients with ulcerative colitis (UC).

99 mission in patients with ulcerative colitis (UC).

100 s a rare complication of ulcerative colitis (UC).

101 nd of surgically managed ulcerative colitis (UC).

102 evealed risk alleles for ulcerative colitis (UC).

103 testinal disease such as ulcerative colitis (UC).

104 Crohn's disease (CD) and ulcerative colitis (UC).

105 trolled trial of FMT for ulcerative colitis (UC).

106 rohn's disease (cCD) and ulcerative colitis (UC).

107 Crohn's disease (CD); 80 ulcerative colitis (UC); 31 controls].

108 's disease [CD], 13 with ulcerative colitis [UC], mean age 45 years [range 19-90], 7 female), and 20

109 tly reduced in SB CD and elevated in colonic UC compared with non-IBD controls.

110 en used to prevent urological complications (UCs), but it requires cystoscopy extraction.

111 ese parameters, we established the composite UC-100 score (1 + 16 x Mayo Clinic stool frequency subsc

112 ng (IBD), bed sharing (CD), tea consumption (UC), high levels of folate (IBD), high levels of vitamin

113 age functionalization of unclosed cryptands (UCs) (11 examples, yield up to 99%).

114 l targeted therapeutic approaches for curing UC.

115 t intermediate acceptors of cellular-derived UC, thereby preventing the saturation of HDL particles a

116 tical role in the flow of macrophage-derived UC to feces, while the plasma increase of APOB-containin

117 bowel diseases (pre-UC) who later developed UC (post-UC) and matched healthy control individuals (HC

118 s not associated with the risk of developing UC (P(trend) = .62).

119 ciations with the gastrointestinal disorders UC, CD and CRC, in comparison to healthy controls.

120 ptive use (IBD), consumption of soft drinks (UC), vitamin D deficiency (IBD), and non-Helicobacter py

121 rize antibiotic prescribing practices during UC encounters, with a focus on respiratory tract conditi

122 rize terminally differentiated dysfunctional UC CD8(+) T cells expressing IL-26, which attenuate acut

123 lation of DNA is broadly documented in early UC, contributing to genetic instability, altered gene ex

124 8 vs 1.6, p < 0.0005) was higher for elderly UC patients.

125 We show that relative to FAP, UC pouches have reduced levels of lithocholic acid and d

126 For UC, adjusted hazard ratios were 1.49 (95% CI = 1.29-1.72

127 For UC, minor inverse associations were observed.

128 IBD-related admissions increased by 50% for UC and 41% for CD, but no change in the proportion of no

129 .8-18.1) for CD, 17.3 (95% CI 13.7-21.8) for UC, and 16.8 (95% CI 13.9-20.3) for IBD.

130 thod can serve as a complementary method for UC analysis.

131 t or exceeded those previously published for UC severity scores.

132 cantly associated with an increased risk for UC (odds ratio, 3.7 [P = .004] and 4.6 [P = .001], respe

133 The macrophage-based therapy strategies for UC are still at an emerging stage.

134 with VDZ vs anti-TNFalpha treatment were for UC: CR, 53.7% vs 31.7%; RB, 66.8% vs 55.8%; and SF, 59.8

135 ered effector T cells in colon explants from UC patients grown ex vivo.

136 riteria to identify patients with hereditary UC susceptibility are insensitive.

137 n 459 in the intervention group and 1,012 in UC.

138 is not an effective therapeutic approach in UC patients with severe, acute colonic haemorrhage.

139 Genome-wide association studies (GWASs) in UC implicate a FCGR2A variant that alters the binding af

140 shion to promote aberrant DNA methylation in UC.

141 an 82% increased risk of 30-day mortality in UC cases (odds ratio: 1.82; confidence interval: 1.19-2.

142 nteric nervous system (ENS) in CD but not in UC.

143 i-TNFalpha as effective treatment options in UC and CD.

144 reliability for predicting severe outcome in UC.

145 Potential outcomes worthy of prediction in UC were determined by surveying 202 experts in pediatric

146 vels and restored colonization resistance in UC-HMA mice.

147 us alleviating the inflammatory responses in UC.

148 gatively correlated with disease severity in UC patients.

149 crophage-based nanotherapeutic strategies in UC.

150 eed extract in delaying the onset of T2DM in UC Davis T2DM rats, a well validated model which closely

151 Broader germline testing in UC, particularly in those of young ages, should be consi

152 mor necrosis factor alpha (anti-TNFalpha) in UC and CD patients in Germany.

153 cterize the spectrum of germline variants in UC and highlight their roles in shaping the natural hist

154 = 85) from patients with active or inactive UC or CD and controls.

155 future population-based studies of incident UC cohorts to adjust for the confounding effects of diff

156 Our data provide insights into UC pathogenesis, and may prioritise future therapies for

157 pective chart review (15 sites) investigated UC and CD patients who were biologic-treatment naive (bi

158 Mechanistically, UC-MSCs express FLT3L that binds to FLT3 on CD1c(+)DCs t

159 Among 1.16 million UC encounters, antibiotics were prescribed during 34% of

160 he management of patients with mild-moderate UC.

161 minary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor F

162 ion in patients with active mild to moderate UC.

163 87 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores >=1)

164 cy and benign disease groups, neither CD nor UC was associated with increased odds of VTE after any o

165 Time to CD (but not UC) diagnosis was significantly longer for psoriasis pat

166 associated with increased risk of CD but not UC.

167 hape association between BMI and CD, but not UC.

168 n of nonelective surgery cases was observed (UC=38% vs 38%; CD=45% vs 42%) among 15,837 intestinal re

169 following siRNA-mediated knockdown of ODC1, UC cells undergo double-strand DNA breaks and apoptosis.

170 s, antibiotics were prescribed during 34% of UC encounters and respiratory conditions accounted for 6

171 Assessing the disease activity of UC is vital for developing a personalized treatment.

172 However, delineating the aetiology of UC is necessary to ultimately achieve disease cure.

173 Conventionally, the assessment of UC is performed by colonoscopy and histopathology.

174 documented 328 cases of CD and 428 cases of UC over 4,949,938 person-years of follow-up.

175 In the colon of UC patients, miR-24 is localized to intestinal epithelia

176 ranscript and histological score at debut of UC can predict severe outcome and the need for anti-TNF

177 vity that precedes the clinical diagnosis of UC and associates with gut microbiota changes.

178 CD was 3.3 +/- 3.2 years and to diagnosis of UC was 3.2 +/- 3.5 years.

179 In addition, family history of UC (2 studies, n = 557; P = .0004), extraintestinal mani

180 lgorithm can be trained to predict levels of UC severity from full-length endoscopy videos.

181 FcgammaR signal strength in a mouse model of UC determined the magnitude of intestinal inflammation a

182 Importantly, the offspring of UC-3 F VLP-immunized dams showed significant protection

183 g pathways that regulate the pathogenesis of UC and summarize the macrophage-based nanotherapeutic st

184 that may be important in the pathogenesis of UC.

185 ctivation in the etiology and progression of UC as well as presumably other cancers.

186 sis had particularly high incidence rates of UC compared with their non-psoriasis peers.

187 rimary outcome was steroid-free remission of UC, defined as a total Mayo score of <=2 with an endosco

188 ar information associated to the severity of UC and are solely based on morphological characteristics

189 This was a retrospective cohort study of UC encounters in the Intermountain Healthcare network.

190 formation for the diagnosis and treatment of UC.

191 cortex and hippocampus without the usage of UC.

192 Finally, we demonstrated the application of UCs as catalysts for synthetically important alkylation

193 dicated staff, without detrimental impact on UC and urinary tract infection rates.

194 tent at diagnosis in consecutive adult-onset UC patients diagnosed at The Ottawa Hospital between 200

195 l disease burden at diagnosis in adult-onset UC patients.

196 tpatient clinic and compare with adult-onset UC.

197 formed, and a diagnostic indication of CD or UC does not play a role.

198 han 1% of psoriasis patients developed CD or UC during follow-up.

199 ate our key findings in adult and paediatric UC cohorts of 408 participants.

200 fecal microbiota profiles, in 206 pediatric UC patients receiving standardised therapy.

201 colitis (ASC), chronically active pediatric UC, cancer and mortality.

202 e-based predictors for outcomes in pediatric UC, which may be used to optimize treatment algorithms.

203 rmined by surveying 202 experts in pediatric UC.

204 ized medicine approach in treating pediatric UC.

205 phenomenon of cooperative photosensitization UC with green emission of the Tb cations upon NIR excita

206 igh-grade immunohistochemically TAg-positive UCs in two renal transplant recipients.

207 antly different between HC, pre-UC, and post-UC samples.

208 Microbiota composition of post-UC samples was different from HC and pre-UC samples; how

209 d in dams colonized with HC, pre-UC, or post-UC microbiota.

210 seases (pre-UC) who later developed UC (post-UC) and matched healthy control individuals (HCs).

211 ost-UC samples was different from HC and pre-UC samples; however, functional analysis showed increase

212 at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC) and matched healthy

213 Mice colonized with or born from pre-UC-colonized dams developed higher fecal proteolytic act

214 were significantly different between HC, pre-UC, and post-UC samples.

215 dult mice and in dams colonized with HC, pre-UC, or post-UC microbiota.

216 suggesting a bacterial component to the pre-UC proteolytic signature.

217 induces SBA deficiency in inflammatory-prone UC patients, which promotes a pro-inflammatory state wit

218 LDL induced the efflux of radiolabeled UC from cultured macrophages, and, in the simultaneous p

219 of HDL, a rapid transfer of the radiolabeled UC from HDL to LDL occurred.

220 nts with ulcerative colitis (UC) and renders UC-HMA mice more susceptible to CDI.

221 vs 42%) among 15,837 intestinal resections (UC=5,297; CD=10,540).

222 nical remission (CR) and symptom resolution (UC: rectal bleeding [RB], stool frequency [SF]; CD: abdo

223 t optimal drug therapy in moderate to severe UC are complex, with limited guidance on comparative eff

224 in adult outpatients with moderate to severe UC included: (1) overall and comparative efficacy of dif

225 tients or inpatients with moderate to severe UC often requires the use of immunomodulator and/or biol

226 nd productivity losses in moderate to severe UC.

227 ct costs in patients with moderate to severe UC.

228 d/or biologic therapy for moderate to severe UC.

229 Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with

230 e affected by DNA methylation in early stage UC.

231 ardship interventions specifically targeting UC settings.

232 line in systolic BP in the intervention than UC group (-5.0 mm Hg, 95% CI -7.1 to -3.0; P < 0.001) an

233 rnal vaccines in cotton rats and report that UC-3 F VLPs significantly increased the neutralizing ant

234 Here, we show that UC patients harbor a high prevalence of pDGVs that trunc

235 The UC-100 score strongly discriminated absence of rectal bl

236 4% (88/137) in the SD vs 59% (81/137) in the UC arm were in care (absolute difference 5%; 95%CI -6-16

237 88/137) in the SD arm vs 59% (81/137) in the UC arm were in care (absolute difference [AD], 5%; 95% c

238 as driven by linkage beyond 12 months in the UC arm.

239 ow-up, we observed 1336 incident CRCs in the UC cohort (1.29 per 1000 person-years) and 9544 incident

240 In the UC cohort, 639 patients died from CRC (0.55 per 1000 per

241 ed MS can delay the onset of diabetes in the UC Davis T2DM rat model to a greater extent than moderat

242 .5%] to 320 [69.7%] individuals) than in the UC group (from 528 [52.2%] to 624 [61.7%] individuals) (

243 t 2 mo postpartum compared with 12.5% in the UC group (P = 0.05).

244 s and fabrication techniques to increase the UC quantum yield at low excitation intensity.

245 novel composite disease activity index (the UC-100 score) with good discriminative performance that

246 rform each other at different subsets of the UC targets.

247 atment success after 1 year (45.2%) than the UC group (27.6%) (relative risk, 1.6 [CI, 1.1 to 2.4]).

248 Two of these alternative pre-F VLPs, the UC-2 F and UC-3 F VLPs, stimulated in mice higher titers

249 tal of 110 participants randomly assigned to UC were provided 1 session of education, and 110 partici

250 ptic mitochondrial protein yield compared to UC from the same amount of tissue, a mouse hippocampus.

251 lation, have been suggested to contribute to UC pathogenesis.

252 the contribution of genetic risk factors to UC pathogenesis has not been systematically defined.

253 ng optimized conditions, the energy transfer UC process could be observed for the first time in nonde

254 Within aromatic organic chromophores, TTA-UC is achieved through several consecutive energy conver

255 Most of the TTA-UC studies are limited to Visible to Visible (Vis to Vis

256 -invasive nature of NIR light coupled to TTA-UC offers new opportunities.

257 ion based molecular photon upconversion (TTA-UC) is an exciting research area for a broad range of ph

258 iplet-triplet annihilation upconversion (TTA-UC) is an unconventional photophysical process that yiel

259 Although, NIR to Vis TTA-UC is known since 2007, the recent five years have witne

260 xamples include, (i) photovoltaics where TTA-UC could lead to utilization of a larger part of the sol

261 Density gradient ultracentrifugation (UC) is currently the only technique that can separate sy

262 d understanding of the mechanisms underlying UC has led to the emergence of new treatments.

263 ing up excited states to reach upconversion (UC) is severely restricted by vibrational quenching mech

264 While UC-associated CD8(+) effector T cells can trigger tissue

265 15 genes were statistically associated with UC based on GEO2R expression analysis.

266 rs8005161 was significantly associated with UC.

267 disability and other outcomes compared with UC.

268 ar of diagnosis with patients diagnosed with UC at age between 40 and 64 years (adult age, A-O).

269 Immunization with UC-3 F VLPs also induced durable levels of high-titer ne

270 -challenged offspring of dams immunized with UC-3 F VLPs than in the lungs of the RSV-challenged offs

271 of the offspring of the dams immunized with UC-3 F VLPs were significantly higher than those in the

272 ared with those without UC, individuals with UC are at increased risk of developing CRC, are diagnose

273 entified in 80 (14%) of 586 individuals with UC.

274 y virus (HIV)-negative 47-year old male with UC after treatment with the alpha4-beta7 integrin inhibi

275 For every patient with UC, we selected matched reference individuals from the t

276 a3 were measured in serum from patients with UC (n = 58), CD (n = 44) and CRC (n = 39) and compared t

277 ing tumour stage into account, patients with UC and CRC remained at increased risk of CRC death (HR 1

278 ic (P/LP) germline variants in patients with UC and identify associated clinical factors.

279 January 2000 to June 2019, 94 patients with UC diagnosed after the age of 65 years (elderly group, E

280 AUROC) curve for separation of patients with UC from healthy controls was 0.972 (95% CI: 0.925-1.020,

281 n-based cohort study of 96 447 patients with UC in Denmark (n=32 919) and Sweden (n=63 528), patients

282 r one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1.25 (

283 r one additional case per 3041 patients with UC per 5 years).

284 30 colonic biopsy samples from patients with UC treated in the UNIFI phase 3 UC clinical studies of u

285 NIFI program of ustekinumab in patients with UC treated with ustekinumab indicated the achievement of

286 Colonic mucosa samples from patients with UC were characterized by expansion of IL17A+ CD161+ effe

287 Patients with UC were selected from national registers and included in

288 of C6Malpha3 were elevated in patients with UC, CD and CRC patients compared to healthy controls (al

289 ich was elevated in serum from patients with UC, CD and CRC.

290 In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an

291 rtality and incident CRC among patients with UC.

292 he impact of indirect costs in patients with UC.

293 ienced on average by 10 to 24% patients with UC.

294 nly), the HR for incident CRC in people with UC was 1.38 (95% CI 1.20-1.60, or one additional case pe

295 The CRC stage distribution in people with UC was less advanced (p<0.0001) than in matched referenc

296 greater decline in phosphate than those with UC.

297 Within UC, colonic ACE2 was elevated in active disease and in p

298 Compared with those without UC, individuals with UC are at increased risk of develop

299 Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire).

300 with the scores from the SIBDQ and the WPAI-UC.